This is often partly why Epidiolex, the star drug of GW Pharmaceuticals cannabinoid-based portfolio, elevated €158.9M previous year following the drug was granted orphan drug designation for therapy of Dravet syndrome through the EMA.Given that the President & CEO and because the Chair of your Board with the Epilepsy Foundation, we have been … Read More